Trial reportBritish journal of clinical pharmacology2005
Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.
Trial report in British journal of clinical pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Clinical pharmacology and therapeutics · 2012Trial
- Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.The Pediatric infectious disease journal · 2009Trial
- Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.Clinical pharmacokinetics · 2008Trial
- Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.European journal of clinical pharmacology · 2007Trial
- Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.Clinical pharmacology and therapeutics · 2012Article
- A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs.Journal of molecular modeling · 2011Article
- Factors influencing lopinavir and atazanavir plasma concentration.The Journal of antimicrobial chemotherapy · 2010Article
- Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.Antimicrobial agents and chemotherapy · 2009Article
- Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.European journal of clinical pharmacology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe influence of efavirenz on lopinavir pharmacokinetics was investigated using a population approach.
methodsForty-five HIV patients treated with lopinavir/ritonavir plus efavirenz (A) and 24 patients treated with lopinavir/ritonavir plus nucleoside/nucleotide reverse transcriptase inhibitors (B) were studied.
resultsA relationship (P < 0.01) was established between the elimination rate constant of lopinavir (k(10)) and treatment with efavirenz. Mean k(10) was higher in group A than in group B (0.3838 vs 0.2810 h(-1)) (P < 0.001, 95% confidence interval for difference between means 0.1004, 0.1052).
conclusionsThese results suggest that lopinavir metabolism is induced by efavirenz.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.